Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Opna Bio (United States)
Homepage:
opnabio.com
Alternate names:
Opna Bio,
Opna Bio, Inc.
ROR:
00esz3k97
OpenAlex ID:
I4405263930
BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia
2024
·
Audrey L. Smith
, Sydney A. Skupa
, et al.
·
JCI Insight
·
14
PDF
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
2023
·
Linda R. Duska
, Dmitriy Zamarin
, et al.
·
JCO Precision Oncology
·
13
RAF inhibitors activate the integrated stress response by direct activation of GCN2
2025
·
Rebecca Gilley
, Andrew M. Kidger
, et al.
·
Nature Communications
·
11
PDF
Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models
2025
·
Connor A. Ott
, Timothy J. Purwin
, et al.
·
Nature Communications
·
8
PDF
Abstract CT160: Phase 1b/2a clinical trial of the oral BET inhibitor PLX2853 as monotherapy for ARID1A mutated gynecologic cancers and in combination with carboplatin for platinum resistant ovarian cance
2023
·
Elizabeth M. Swisher
, Linda R. Duska
, et al.
·
Cancer Research
·
3
Abstract 660: OPN-6602, a potent dual EP300/CBP bromodomain inhibitor, targets multiple myeloma through concomitant suppression of IRF4 and c-MYC
2024
·
Bernice Matusow
, Wayne Spevak
, et al.
·
Cancer Research
·
2
Abstract 7264: OPN-9840, a non-covalent potent pan-TEAD inhibitor, exhibits single agent efficacy in preclinical malignant mesothelioma models
2024
·
Pan-Yu Chen
, Bernice Matusow
, et al.
·
Cancer Research
·
2
BET inhibitor OPN-2853 in advanced solid tumors and lymphoma: results from the phase 1b PLX124-01 trial
2026
·
Michael S. Gordon
, Richard D. Carvajal
, et al.
·
Cancer Chemotherapy and Pharmacology
·
1
Overcoming the Limits of Inhibition: Mutant-Selective BRAF Degraders
2026
·
Pan-Yu Chen
, Gideon Bollag
·
Cancer Research
·
1
OPN-6602, an Orally Bioavailable EP300/CBP Bromodomain Inhibitor, Targets Multiple Myeloma through Suppression of IRF4 and MYC
2024
·
Bernice Matusow
, Sadegh Saghafinia
, et al.
·
Blood
·
1
A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma
2024
·
Jackie M. Walling
, Bernice Matusow
, et al.
·
Blood
·
1
PDF
Abstract C085: OPN-6602, a dual EP300/CBP bromodomain inhibitor modulates androgen-driven transcription, including MYC, in mCRPC
2023
·
Bernice Matusow
, Wayne Spevak
, et al.
·
Molecular Cancer Therapeutics
·
1
Acute Myeloid Leukemia Relapse after Bromodomain Inhibitor Treatment or Chemotherapy is Characterized by Myc-Ras Transcriptional Remodeling
2025
·
Benjamin J. Huang
, Jeevitha D’Souza
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
Novel multifunctional degraders of EP300/CBP and IKZF1/3 with potent anti-myeloma activity
2025
·
Pan-Yu Chen
, Somenath Chowdhury
, et al.
·
Blood
PDF
Interim analysis of promise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis experiencing an inadequate response to ruxolitinib
2025
·
Adam Mead
, Bethan Psaila
, et al.
·
Blood
PDF
Abstract C024: CBP/EP300 inhibitor OPN-6602 in marginal zone lymphomas: preclinical activity as a single agent and in combination with BTK inhibition
2025
·
Maidel Carpio
, Alberto Jesus. Arribas
, et al.
·
Molecular Cancer Therapeutics
Abstract 7201: Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models
2024
·
Connor A. Ott
, Timothy Purwin
, et al.
·
Cancer Research
Inhibition of Bromodomain and Extraterminal Domain (BET) Proteins Alleviates Chronic Graft- Versus-Host-Disease Via Modulating the CXCR5/CXCL13 Axis
2023
·
Rathan Kumar
, Lotus Neidermire-Colley
, et al.
·
Blood
PDF
Abstract 6396: BET inhibition alleviates T-cell dysfunction in chronic lymphocytic leukemia
2023
·
Audrey L. Smith
, Alexandria P. Eiken
, et al.
·
Cancer Research
Show more works
View as search
Works count:
19
Citation count:
58
Year
Topic
Type